Abstract

EDARAVONE: A REVIEW ON ANALYTICAL METHOD AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS

Margi Patel*, Krutika Patel, Khushbu Patel and Dr. C. N. Patel

.

Abstract

Over the last decade, important advances have been made to support the fact that reactive oxygen species (ROS) are generated and play a harmful role during the acute and late stages of cerebral ischemia. Several drugs, such as radical scavengers and antioxidants, have been evaluated in preclinical and clinical studies. Edaravone is a novel antioxidant that is currently used in Japan for the treatment of patients in the acute stage of cerebral infarction. In particular, postischemic inflammation, leading to brain edema and infarction due to neuronal damage and endothelial cell death, can be ameliorated by Edaravone. In addition to these antistroke effects, edaravone has also been shown to prevent oxidative damage to various extracerebral organs. Therefore, in addition to its usefulness in the treatment of stroke, Edaravone is expected to play an integral role in the treatment of many oxidative stress-related diseases. Edaravone is used to treat amyotrophic lateral sclerosis (ALS, Lou Gehrig's disease; a condition in which the nerves that control muscle movement slowly die, causing the muscles to shrink and weaken). Edaravone is in a class of medications called antioxidants.

Keywords: Edaravone, ALS, Antioxidants, Scavenger.